Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.46 |
| ▸ | KCNJ3 | P48549 | 11/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381208 | 0.83 | ANPEP (0.45) | NOTUMMAPK14POLBLMNA | |
| SCHEMBL16332319 | 0.82 | NOTUM (0.54) | NOTUMPOLB | |
| SCHEMBL4376341 | 0.80 | MAPK14 (0.42) | NOTUMMAPK14POLBLMNA | |
| SCHEMBL4383249 | 0.77 | CA1 (0.41) | MAPK14POLBLMNA | |
| SCHEMBL4384792 | 0.76 | MAPK14 (0.56) | NOTUMMAPK14KCNJ5KCNJ3 | |
| SCHEMBL4389760 | 0.74 | APLNR (0.54) | MAPK14POLB | |
| SCHEMBL4376136 | 0.73 | MAPK14 (0.62) | NOTUMMAPK14KCNJ5KCNJ3 | |
| SCHEMBL4390112 | 0.71 | L3MBTL1 (0.57) | NOTUMMAPK14KCNJ5KCNJ3 | |
| SCHEMBL4381315 | 0.70 | POLB (0.40) | NOTUMKCNJ5KCNJ3POLBLMNA | |
| SCHEMBL24759473 | 0.69 | POLB (0.36) | KCNJ5KCNJ3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | NOTUM 3993/4885MAPK14 41/4885KCNJ5 1929/4885 |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | LTB4R2, LTB4R, MAPK1 | NOTUM 1936/4885MAPK14 79/4885KCNJ5 1240/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | NOTUM 4121/4885MAPK14 53/4885KCNJ5 1887/4885 |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | MAPK1, MAPK6, MAP3K6 | NOTUM 4231/4885MAPK14 46/4885KCNJ5 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.